Biogen Inc. has withdrawn its European marketing authorization application for the Alzheimer's drug aducanumab, leading to a more than 3% drop in share price. The company struggled to demonstrate the drug's benefits to regulators, raising concerns among investors. Despite this setback, Biogen remains committed to developing Alzheimer's treatments and is investing $250 million over 20 years to enhance its green chemistry initiatives.
“Biogen · was the first company · in the life sciences industry · to become carbon neutral in 2014”
“Biogen · aims · to achieve greater than 90% of green chemistry targets · by 2030”
“Biogen · is committed to · a 20 year, 250 million dollar investment · to become fossil fuel free”
“Biogen Inc · has decided to withdraw · European marketing authorization application · for its troubled Alzheimer's drug, aducanumab”
“Biogen Inc · failed to convince · the regulator · of its benefits”
“Biogen Inc · sought · a re-examination · of the agency's decision”
“BIIB shares · are down · 3.16% · at $211.50 during the market session”
“Biogen Inc. · shares fell · 2% · Friday”
“Biogen Inc. · withdrew the marketing authorization application · aducanumab · the European regulator”
“Biogen Inc · shares fell · more than 3% · Friday”
“Biogen Inc · pulled its Marketing Authorization Application · aducanumab · in Europe”
“Biogen · stands by the safety and efficacy · aducanumab”